G. Citterio

发表

Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy.

A. Santoro, L. Rimassa, M. Tronconi, 2010, European journal of cancer.

Reversible anergy in circulating lymphocytes of cancer patients during interleukin-2 therapy

E. Clementi, C. Fortis, G. Citterio, 1994, Cancer Immunology, Immunotherapy.

Increased interleukin-10 serum levels in patients with solid tumours.

M. Braga, L. Gianotti, C. Fortis, 1996, Cancer letters.

Targeted delivery of TNF using NGR-TNF in combination with chemotherapy as an effective and tolerable strategy in a hepatocarcinoma patient

A. Corti, M. Giovannini, E. Villa, 2008 .

Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients

G. Scambia, V. Masciullo, C. Bordignon, 2012, British Journal of Cancer.

In vivo administration of GM‐CSF promotes the clearance of apoptotic cells: effects on monocytes and polymorphonuclear leukocytes

C. Rugarli, A. Manfredi, S. Heltai, 2000, Journal of leukocyte biology.

Present and future treatment options for primary CNS lymphoma

M. Reni, A. Ferreri, G. Citterio, 2015, Expert opinion on pharmacotherapy.

Primary central nervous system lymphoma.

M. Reni, G. Gatta, A. Ferreri, 2017, Critical reviews in oncology/hematology.

Interleukin-2, Interferon-α and Interleukin-2 plus Interferon-α in Renal Cell Carcinoma. A Randomized Phase Ii Trial

F. Cognetti, F. Boccardo, A. Rubagotti, 1998, Tumori.

Current uses of radiation therapy in patients with primary CNS lymphoma

M. Reni, G. Citterio, Andrés José María Ferreri, 2013, Expert review of anticancer therapy.

Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

C. Punt, C. V. van Herpen, C. Bordignon, 2009, British Journal of Cancer.

Sequential therapy with recombinant Interleukin-2 (rIL-2) and α-interferon (IFN) for advanced renal cell cancer (rcc) : a preliminary report

A. Borri, C. Besana, C. Rugarli, 1994 .

The Feasibility of Repetitive Courses of High-Dose Continuous Intravenous Infusion Interleukin-2 and Subcutaneous Alpha-Interferon with Polychemotherapy in Advanced Malignant Melanoma

D. Polastri, R. Guerrieri, M. Foppoli, 1995, Tumori.

Plasma nitrate plus nitrite changes during continuous intravenous infusion interleukin 2.

G. Fragasso, M. Tresoldi, C. Rugarli, 1996, British Journal of Cancer.

Prognostic factors for survival in metastatic renal cell carcinoma: retrospective analysis from 109 consecutive patients.

A. Bertuzzi, M. Tresoldi, C. Rugarli, 1997, European urology.

Challenges and prospects in the diagnosis and treatment of primary central nervous system lymphoma

T. Calimeri, A. Ferreri, G. Citterio, 2018, Expert review of neurotherapeutics.

Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors

Roberto Scalamogna, Vanesa Gregorc, F. D. De Braud, 2011, Clinical Cancer Research.

Cancer Therapy : Clinical Phase I Study of NGR-hTNF , a Selective Vascular Targeting Agent , in Combination with Cisplatin in Refractory Solid Tumors

Roberto Scalamogna, Vanesa Gregorc, C. Bordignon, 2011 .

Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.

G. Ceresoli, F. D. De Braud, P. Bruzzi, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours.

P. Scifo, F. Dell’Acqua, P. Bruzzi, 2010, European journal of cancer.

Serum levels of soluble cell adhesion molecules (ICAM-1, VCAM-1, E-selectin) and of cytokine TNF-alpha increase during interleukin-2 therapy.

C. Fortis, G. Citterio, L. Galli, 1995, Clinical immunology and immunopathology.

Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial.

T. Calimeri, F. Fallanca, A. Corti, 2020, Blood advances.

R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma.

T. Calimeri, F. Fallanca, A. Corti, 2019, Blood.

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma

F. D. De Braud, A. Santoro, S. Bozzarelli, 2010, British Journal of Cancer.

Risk‐tailored CNS prophylaxis in a mono‐institutional series of 200 patients with diffuse large B‐cell lymphoma treated in the rituximab era

A. Vignati, M. Ponzoni, A. Ferreri, 2015, British journal of haematology.

High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial.

M. Di Nicola, A. Ferreri, F. Ciceri, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon.

M. Tresoldi, A. Borri, C. Besana, 1994, European journal of cancer.

Reduction of brain metastasis following immunotherapy with interleukin-2 for stage IV renal cell cancer.

C. Rugarli, M. Baldini, G. Citterio, 1997, Acta oncologica.

Intensive chemotherapy with recombinant-human granulocyte-macrophage colony stimulating factor (r-hu-gm-csf) for small cell lung cancer (sclc): a pilot study

M. Tresoldi, M. Marcatti, A. Borri, 1994 .

Isolated left ventricular filling abnormalities may predict interleukin-2-induced cardiovascular toxicity.

S. Chierchia, G. Fragasso, M. Tresoldi, 1996, Journal of Immunotherapy with Emphasis on Tumor Immunology.

NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM) .

C. Bordignon, P. Zucali, F. De Vincenzo, 2011, Journal of Clinical Oncology.

Cytokine secretion associated with the clearance of apoptotic bodies in renal cell carcinoma patients

A. Borri, C. Rugarli, A. Manfredi, 2001, International journal of cancer.

A phase I study to define the optimal low dose of NGR-hTNF, a novel vascular targeting agent (VTA), in combination with cisplatin in patients (pts) with solid tumors

C. Bordignon, M. Giovannini, F. Braud, 2008 .